CC BY-NC-ND 4.0 · Laryngorhinootologie 2019; 98(S 02): S86-S87
DOI: 10.1055/s-0039-1686098
Abstracts
Oncology

Influence of Podoplanin Expression on Prognosis in Nasopharyngeal Carcinoma

P Wolber
1   Uniklinik Köln, Klinik und Poliklinik für HNO-Heilkunde, Köln
,
M Niemczyk
2   Uniklinik Köln, Klinik und Poliklinik für Hals-, Nasen- und Ohrenheilkunde, Köln
,
JP Klußmann
2   Uniklinik Köln, Klinik und Poliklinik für Hals-, Nasen- und Ohrenheilkunde, Köln
,
M Meyer
2   Uniklinik Köln, Klinik und Poliklinik für Hals-, Nasen- und Ohrenheilkunde, Köln
› Author Affiliations
 
 

    Introduction:

    Podoplanin is a membrane-bound glycoprotein that plays a role in lymphangiogenesis. Several studies suggest a role of podoplanin in head and neck cancer. The purpose of the current study was to evaluate the role of podoplanin as a prognostic marker in nasopharyngeal carcinoma.

    Methods:

    In a monocentric retrospective analysis data of 42 patients with primary diagnosis of nasopharyngeal carcinoma (diagnosed between 2004 – 2013) were examined for the relationship between the immunohistochemically analyzed podoplanin expression status (monoclonal antibody D2 – 40) and corresponding clinical and oncological parameters.

    Results:

    Fifty percent of the patients were female. The average age was 57 years. The majority (68%) had an advanced tumor stage (T3-T4). The 5-year overall survival was 54%.

    33% showed a positive expression of podoplanin. In patients with tumors with podoplanin expression, 5-year overall survival was 15%, while in patients with tumors without podoplanin expression 5-year overall survival was 75% (p = 0.017, univariate analysis). In multivariate analysis, podoplanin expression was shown to be the only independent prognostic marker for nasopharyngeal carcinoma (p = 0.025).

    Conclusions:

    This retrospective study shows that podoplanin expression is a potential prognostic marker for nasopharyngeal carcinomas. In the future, clinical use could filter out aggressive courses and allow an intensification of therapy.


    #
    MD MSc Philipp Wolber
    Univ. HNO-Klinik,
    Kerpenerstr. 62, Gebäude 23, 50937
    Köln

    Publication History

    Publication Date:
    23 April 2019 (online)

    © 2019. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

    Georg Thieme Verlag KG
    Stuttgart · New York